210 related articles for article (PubMed ID: 36271606)
21. Parafibromin Abnormalities in Ossifying Fibroma.
Costa-Guda J; Pandya C; Strahl M; Taik P; Sebra R; Chen R; Uzilov AV; Arnold A
J Endocr Soc; 2021 Jul; 5(7):bvab087. PubMed ID: 34159287
[TBL] [Abstract][Full Text] [Related]
22. Hyperparathyroidism-jaw tumor syndrome: a report of three large kindred.
Iacobone M; Masi G; Barzon L; Porzionato A; Macchi V; Ciarleglio FA; Palù G; De Caro R; Viel G; Favia G
Langenbecks Arch Surg; 2009 Sep; 394(5):817-25. PubMed ID: 19529956
[TBL] [Abstract][Full Text] [Related]
23. CDC73-Related Disorders: Clinical Manifestations and Case Detection in Primary Hyperparathyroidism.
van der Tuin K; Tops CMJ; Adank MA; Cobben JM; Hamdy NAT; Jongmans MC; Menko FH; van Nesselrooij BPM; Netea-Maier RT; Oosterwijk JC; Valk GD; Wolffenbuttel BHR; Hes FJ; Morreau H
J Clin Endocrinol Metab; 2017 Dec; 102(12):4534-4540. PubMed ID: 29040582
[TBL] [Abstract][Full Text] [Related]
24. A Young Male with Parafibromin-Deficient Parathyroid Carcinoma Due to a Rare Germline HRPT2/CDC73 Mutation.
Kapur A; Singh N; Mete O; Hegele RA; Fantus IG
Endocr Pathol; 2018 Dec; 29(4):374-379. PubMed ID: 30361844
[TBL] [Abstract][Full Text] [Related]
25. Crystal structure of the N-terminal domain of human CDC73 and its implications for the hyperparathyroidism-jaw tumor (HPT-JT) syndrome.
Sun W; Kuang XL; Liu YP; Tian LF; Yan XX; Xu W
Sci Rep; 2017 Nov; 7(1):15638. PubMed ID: 29142233
[TBL] [Abstract][Full Text] [Related]
26. CDC73 intragenic deletion in familial primary hyperparathyroidism associated with parathyroid carcinoma.
Korpi-Hyövälti E; Cranston T; Ryhänen E; Arola J; Aittomäki K; Sane T; Thakker RV; Schalin-Jäntti C
J Clin Endocrinol Metab; 2014 Sep; 99(9):3044-8. PubMed ID: 24823466
[TBL] [Abstract][Full Text] [Related]
27. [CDC73 mutations in young patients with primary hyperparathyroidism: A description of two clinical cases].
Mamedova EO; Mokrysheva NG; Pigarova EA; Przhiyalkovskaya EG; Voronkova IA; Vasilyev EV; Petrov VM; Gorbunova VA; Rozhinskaya LY; Belaya ZE; Tyulpakov AN
Ter Arkh; 2016; 88(10):57-62. PubMed ID: 27801421
[TBL] [Abstract][Full Text] [Related]
28. Defective nucleolar localization and dominant interfering properties of a parafibromin L95P missense mutant causing the hyperparathyroidism-jaw tumor syndrome.
Panicker LM; Zhang JH; Dagur PK; Gastinger MJ; Simonds WF
Endocr Relat Cancer; 2010 Jun; 17(2):513-24. PubMed ID: 20304979
[TBL] [Abstract][Full Text] [Related]
29. A two-generation hyperparathyroidism-jaw tumor (HPT-JT) syndrome family: clinical presentations, pathological characteristics and genetic analysis: a case report.
Yang D; Zheng J; Tang F; He Q; Huang H; Zhou P
Diagn Pathol; 2022 Sep; 17(1):71. PubMed ID: 36153594
[TBL] [Abstract][Full Text] [Related]
30. Hyper Parathyroidisim Jaw Tumor Syndrome: A Rare Condition of Incongruous Features.
Redwin Dhas MP; Karthiga KS; Tatu JE; Eugenia SJ
Ethiop J Health Sci; 2017 May; 27(3):309-313. PubMed ID: 29217931
[TBL] [Abstract][Full Text] [Related]
31. Detection of the first gross CDC73 germline deletion in an HPT-JT syndrome family.
Cascón A; Huarte-Mendicoa CV; Javier Leandro-García L; Letón R; Suela J; Santana A; Costa MB; Comino-Méndez I; Landa I; Sánchez L; Rodríguez-Antona C; Cigudosa JC; Robledo M
Genes Chromosomes Cancer; 2011 Nov; 50(11):922-9. PubMed ID: 21837707
[TBL] [Abstract][Full Text] [Related]
32. Characterization of a new CDC73 missense mutation that impairs Parafibromin expression and nucleolar localization.
Masi G; Iacobone M; Sinigaglia A; Mantelli B; Pennelli G; Castagliuolo I; Palù G; Barzon L
PLoS One; 2014; 9(5):e97994. PubMed ID: 24842573
[TBL] [Abstract][Full Text] [Related]
33. Frequent large germline HRPT2 deletions in a French National cohort of patients with primary hyperparathyroidism.
Bricaire L; Odou MF; Cardot-Bauters C; Delemer B; North MO; Salenave S; Vezzosi D; Kuhn JM; Murat A; Caron P; Sadoul JL; Silve C; Chanson P; Barlier A; Clauser E; Porchet N; Groussin L;
J Clin Endocrinol Metab; 2013 Feb; 98(2):E403-8. PubMed ID: 23293331
[TBL] [Abstract][Full Text] [Related]
34. Genotype of CDC73 germline mutation determines risk of parathyroid cancer.
Li Y; Zhang J; Adikaram PR; Welch J; Guan B; Weinstein LS; Chen H; Simonds WF
Endocr Relat Cancer; 2020 Sep; 27(9):483-494. PubMed ID: 32590342
[TBL] [Abstract][Full Text] [Related]
35. Hyperparathyroidism-jaw tumor syndrome: Results of operative management.
Mehta A; Patel D; Rosenberg A; Boufraqech M; Ellis RJ; Nilubol N; Quezado MM; Marx SJ; Simonds WF; Kebebew E
Surgery; 2014 Dec; 156(6):1315-24; discussion 1324-5. PubMed ID: 25444225
[TBL] [Abstract][Full Text] [Related]
36. Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors.
Cetani F; Marcocci C; Torregrossa L; Pardi E
Endocr Relat Cancer; 2019 Jul; 26(7):R441-R464. PubMed ID: 31085770
[TBL] [Abstract][Full Text] [Related]
37. Long-Term Outcomes of Parathyroidectomy in Hyperparathyroidism-Jaw Tumor Syndrome: Analysis of Five Families with CDC73 Mutations.
Iacobone M; Camozzi V; Mian C; Pennelli G; Pagetta C; Casal Ide E; Masi G; Zovato S; Torresan F
World J Surg; 2020 Feb; 44(2):508-516. PubMed ID: 31493194
[TBL] [Abstract][Full Text] [Related]
38. A large extended family with hyperparathyroidism-jaw tumor syndrome due to deletion of the third exon of CDC73: clinical and molecular features.
Le Collen L; Barraud S; Braconnier A; Coppin L; Zachar D; Boulagnon C; Deguelte S; Souchon PF; Spodenkiewicz M; Poirsier C; Aubert S; Odou MF; Delemer B
Endocrine; 2021 Sep; 73(3):693-701. PubMed ID: 33999366
[TBL] [Abstract][Full Text] [Related]
39. HIGH RISK OF PARATHYROID CARCINOMA AND GENETIC SCREENING IN THE FIRST DIAGNOSED ROMANIAN FAMILY WITH HYPERPARATHYROIDISM-JAW TUMOR SYNDROME AND A GERMLINE MUTATION OF THE CDC73 GENE.
Grigorie D; Sucaliuc A; Ciuffi S; Franceschelli F; Marini F; Ioachim D; Terzea D; Brandi MLL
Acta Endocrinol (Buchar); 2019; 15(3):398-403. PubMed ID: 32010362
[TBL] [Abstract][Full Text] [Related]
40. Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment.
Cetani F; Pardi E; Ambrogini E; Banti C; Viacava P; Borsari S; Bilezikian JP; Pinchera A; Marcocci C
J Endocrinol Invest; 2008 Oct; 31(10):900-4. PubMed ID: 19092296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
